List of Thiola Ec drug patents

Thiola Ec is owned by Mission Pharmacal Co.

Thiola Ec contains Tiopronin.

Thiola Ec has a total of 1 drug patent out of which 0 drug patents have expired.

Thiola Ec was authorised for market use on 28 June, 2019.

Thiola Ec is available in tablet, delayed release;oral dosage forms.

Thiola Ec can be used as a method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria.

The generics of Thiola Ec are possible to be released after 14 November, 2038.

THIOLA EC Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458104 MISSION PHARMACAL CO NA
Nov, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
ODE* (ODE*) Jun 28, 2026

Drugs and Companies using TIOPRONIN ingredient

Market Authorisation Date: 28 June, 2019

Treatment: A method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of THIOLA EC before it's patent expiration?
More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in